Professor
Hematology
Dr. Steven M. Kornblau, MD
|
|
Give Review
Steven Kornblau works in the field of Hematology. He went to Baylor College of Medicine. Dr. Steven M. Kornblau is a published doctor. He published 74 publications, including: 'PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.' He is registered with Medicare.
Publications
- Anti-apoptotic ARC protein confers chemoresistance by controlling Leukemia-microenvironment interactions through a NFκB/IL1β signaling network.
- Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia.
- PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated Leukemia in NHD13 mice.
- Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
- Are changes in HLA Ags responsible for Leukemia relapse after HLA-matched allogeneic hematopoietic SCT?
- Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia.
- Clonal evolution of Acute myeloid leukemia relapsed after 19 years of remission.
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed Acute myeloid leukemia and Acute lymphoblastic leukemia.
- A genome-wide association study of susceptibility to Acute lymphoblastic leukemia in adolescents and young adults.
- Biological properties of ligand-dependent activation of the MET receptor kinase in Acute myeloid leukemia.
- Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signa...
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia.
- Loss of TRIM62 Expression Is an Independent Adverse Prognostic Factor in Acute Myeloid Leukemia.
- Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with Acute lymphoblastic leukemia (ALL).
- The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in Acute myeloid leukemia cells.
- Implications of the miR-10 family in chemotherapy response of NPM1 mutated AML.
- Design, development, and validation of a high-throughput drug-screening assay for targeting of human Leukemia.
- Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents.
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia.
- WTAP is a novel oncogenic protein in Acute myeloid leukemia.
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in Myeloid malignancies.
- Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.
- BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia.
- Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.
- Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic Leukemia.
- A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of Myelodysplastic syndrome.
- Prognostic impact and targeting of CRM1 in Acute myeloid leukemia.
- Notch activation inhibits AML growth and survival: a potential therapeutic approach.
- The epigenome of AML stem and progenitor cells.
- Molecular characterization of de novo Philadelphia chromosome-positive Acute myeloid leukemia.
- Clinical and proteomic characterization of Acute myeloid leukemia with mutated RAS.
- Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in Acute myelogenous leukemia cells.
- Regulation of HIF-1α signaling and chemoresistance in Acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
- Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML under conditions mimicking the bone marrow microenvironment.
- Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid Leukemia progression and with chronic phase in the CD34-pos...
- Abnormal expression of friend leukemia virus integration 1 protein is an adverse prognostic factor in Acute myeloid leukemia.
- Lenalidomide as initial therapy of elderly patients with chronic lymphocytic Leukemia.
- Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate Acute lymphoblastic leukemia.
- Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.
- Upregulation of homeodomain genes, DLX1/2, by FLT3 signaling.
- Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.
- Use of reverse phase protein microarrays to study protein expression in Leukemia: technical and methodological lessons learned.
- Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in Acute myelogenous leukemia and myelodysplasia.
- Dynamic single-cell network profiles in Acute myelogenous leukemia are associated with patient response to standard induction therapy.
- Highly phosphorylated FOXO3A is an adverse prognostic factor in Acute myeloid leukemia.
- Dasatinib inhibits the growth of molecularly heterogeneous myeloid Leukemias.
- Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines.
- Functional characterization of FLT3 receptor signaling deregulation in Acute myeloid leukemia by single cell network profiling (SCNP).
- MicroRNA 29b functions in Acute myeloid leukemia.
- Overexpression of ZNF342 by juxtaposition with MPO promoter/enhancer in the novel translocation t(17;19)(q23;q13.32) in pediatric Acute myeloid leukemia and analysis o...
- Functional proteomic profiling of AML predicts response and survival.
- HOX expression patterns identify a common signature for favorable AML.
- MicroRNA signatures associated with cytogenetics and prognosis in Acute myeloid leukemia.
- Aberrant EVI1 expression in Acute myeloid leukemias associated with the t(3;8)(q26;q24).
- The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early Acute graft-versus-host disease mortality.
- Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
- Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent Acute promyelocytic leukemia.
- Studying the right cell in Acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-viv...
- Simultaneous activation of multiple signal transduction pathways confers poor prognosis in Acute myelogenous leukemia.
- Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary Leukemia specimens and hematopoietic stem cells.
- Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in Acute myelo...
- Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in Leukemias.
- Recommended guidelines for the treatment of cancer treatment-induced diarrhea.
- Treatment of Philadelphia chromosome-positive Acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
- Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis.
- Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous Leukemia with imatinib mesylate.
- Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid Leukemia after failure of interferon-alpha: follow-up results.
- DNA methylation of multiple promoter-associated CpG islands in adult Acute lymphocytic leukemia.
- Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in Acute myelogenous leukemia.
- Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.
- Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells.
- Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
- PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.
Schools
Univ Of Tx Med Branch Galveston
St Lukes Episcopal Hospital
Baylor Affil Hospital
Utscc Md Anderson Hospital
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Leukocytosis
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas MD Anderson Cancer Center -
Baylor College of Medicine -
University of Texas Medical Branch
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1184723827 | |
| NPPES Provider LastName | KORNBLAU | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 163.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184723827 |
| Last Name Of The Provider | KORNBLAU |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
|
Dr. Luhua M. Wang, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janet C. Tu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Araujo, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mohammad Riaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Uday R. Popat, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Charles L. Yen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gautam Borthakur, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Ulas D. Bayraktar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hesham M. Amin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gabriel N. Hortobagyi, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David S. Hong, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Swaminathan P. Iyer, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Abdul-Masih F P. Farha, MD |
|
|
Mohamed Haq, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Miguel A. Escobar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jesus H. Hermosillo, MD |
|
|
Dr. Partow Kebriaei, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Seung T. Lee, MD |
|
|
Michael W. Thompson |